Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma

• Status: Withdrawn
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the response rate of daily low dose interferon-alpha-2b in patients with metastatic or unresectable clear cell renal cell carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Treatments: Interferon alpha-2; Interferon-alpha; Interferons

Criteria

Inclusion Criteria:

• Metastatic or unresectable clear cell renal cell carcinoma

• Measurable disease

Exclusion Criteria:

• Prior interferon therapy

• More than 3 prior therapy regimens